Tipsheet
What matters at India’s listed companies
Concalls · Trading · Micro cap

Vasa Denticity pulls FY27 guidance after stock-outs crushed margins

The dental marketplace now says it was 'immature' handling capital markets. FY26 core revenue grew 33%, but a supply crisis cut Q4 EBITDA to 4%.


Mkt cap₹754 cr
P/E73.69×
ROE12.80%
Debt / eq.0.00
₹283 cr FY26 total income from continuing operations.

What's new

  • Vasa Denticity has retracted its earlier FY27 revenue guidance of ₹500-600 crore.
  • Management attributed the reversal to 'immaturity in handling capital markets.'
  • A stock-out crisis pushed Q4 gross margins to 23.7% and EBITDA margins to 4%.

Why this matters

A guidance retraction on operational grounds, not market headwinds, is a sharper signal of internal dysfunction. The company built a growth story on a 33% revenue trajectory, then admitted its supply chain couldn't keep pace. The next test is whether 'much better than last year' is guidance or wishful thinking.

What we're watching

  • The pace of own-brand inventory normalization through Q1 and Q2.
  • Whether FY26's 33% core growth holds up without the guided revenue ceiling.
  • Management's explanation for the 'tactical execution failures' that caused the stock-out.

The full read

Vasa Denticity pulled its FY27 revenue guidance of ₹500-600 crore from the table, calling its earlier target a product of 'immaturity in handling capital markets.' The retraction follows a painful Q4 in which a self-inflicted stock-out crisis pushed gross margins to 23.7% and EBITDA to 4%. The company's core business grew 33% in FY26 to ₹283 crore, which makes the supply-chain collapse more damaging: it wasn't a demand problem, it was an execution one. Management now says own-brand inventory should normalize and FY27 will be 'much better than last year,' but this is a qualitative claim, not guidance. For investors, the key risk is that a company selling growth stumbled on the basics. The next proof point is operational recovery, not a new target number.

Questions answered

Why did Vasa Denticity retract its FY27 revenue guidance?
Management cited 'immaturity in handling capital markets' and the inability to deliver the ₹500-600 crore target it had previously set. The retraction followed a disclosure that supply-chain failures severely impacted recent profitability.
How bad was the stock-out crisis?
It pushed Q4 gross margins down to 23.7% and EBITDA margins to just 4%. Management called the breakdown a 'tactical execution failure' in its own-brand inventory management.
What was the core business performance in FY26?
Total income from continuing operations hit ₹283 crore, with the core business growing 33% year-on-year. The operational collapse happened despite this top-line expansion.
What is management's outlook for FY27?
They expect FY27 to be 'much better than last year,' contingent on own-brand stock levels normalizing. This is a directional comment, not a numerical forecast, after the earlier guidance was retracted.
Mentioned: FY27 guidance of ₹500-600 cr · ₹283 cr FY26 revenue · Q4 EBITDA at 4%
Primary source NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.